← Back to all trials
Not Yet Recruiting
NCT07226466
Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
Conditions: Brain Tumor Adult, Brain Metastases From Solid Tumors, Brain Tumor, Primary, Brain Tumor
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 40
Sponsor: University of California, San Francisco
Location: University of California, San Francisco San Francisco California
Summary
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.
Eligibility Criteria
Inclusion Criteria:
1. \>= 18 years old
2. Diagnosis of a primary brain tumor OR #3. Not both #2 and #3.
3. Diagnosis of primary solid tumor and secondary involvement of the brain
4. If the patient has brain metastases: fewer than 5 brain metastases (post-operative and definitive allowed), none \> 1 cm in max diameter.
5. Candidate for standard of care / usual care (SOC) focused brain radiotherapy.
6. No prior brain radiotherapy, including whole brain radiotherapy.
7. Eastern Cooperative Oncology Group (ECOG) functional score 0 or 1.
8. Estimated life expectancy post-treatment of \> 2 years.
Exclusion Criteria:
1. Diagnosis of neurodegenerative disease (Alzheimer's disease, Parkinson's disease).
2. Diagnosis of memory disorder pre-treatment.
3. Leptomeningeal disease or disease involving either hippocampus.
Source: ClinicalTrials.gov (NCT07226466). StuddyBuddy aggregates publicly available trial information.
